ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies
Leadership & Corporate
Read more 
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
Science & Medicine
Read more ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
Science & Medicine
Read more 
STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news